A. Winston

发表

Magnetic Resonance Imaging of Cerebral Small Vessel Disease in Men Living with HIV and HIV-Negative Men Aged 50 and Above.

S. Ourselin, X. Golay, C. Sudre, 2019, AIDS research and human retroviruses.

Gray and White Matter Abnormalities in Treated Human Immunodeficiency Virus Disease and Their Relationship to Cognitive Function

Robert Leech, David J Sharp, Peter Reiss, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.

A. Winston, S. Taylor-Robinson, D. Cooper, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Associations between widespread pain and sleep quality in people with HIV.

S. Redline, A. Winston, C. Sabin, 2020, Journal of acquired immune deficiency syndromes.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

The ‘COmorBidity in Relation to AIDS’ (COBRA) cohort: Design, methods and participant characteristics

C. Franceschi, A. Winston, C. Sabin, 2018, PloS one.

Clinical research cerebral MRI findings in HIV-positive subjects and appropriate controls

D. Sharp, A. Waldman, A. Winston, 2018, AIDS.

Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.

Delpech, B. Gazzard, C. Leen, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease.

A. Winston, J. Underwood, Joseph Scott, 2016, The British journal of radiology.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

D. Podzamczer, B. Clotet, A. Winston, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Differences in the variability of cerebral proton magnetic resonance spectroscopy (1H-MRS) measurements within three HIV-infected cohorts

A. Winston, S. Taylor-Robinson, L. Garvey, 2015, The neuroradiology journal.

Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers

D. Sharp, C. Franceschi, B. Berkhout, 2017, The Journal of infectious diseases.

Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus–positive Patients Treated With Protease Inhibitor Monotherapy

X. Golay, M. Cardoso, L. Haddow, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Brain perfusion, regional volumes and cognitive function in HIV positive patients treated with protease inhibitor monotherapy.

X. Golay, M. Cardoso, L. Haddow, 2018 .

Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study

B. Gazzard, C. Leen, D. Pillay, 2009, Journal of acquired immune deficiency syndromes.

Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV

A. Winston, C. Sabin, S. Khoo, 2021, PloS one.

Evolution of changes in cognitive function after the initiation of antiretroviral therapy

A. Winston, J. Underwood, Stephen Taylor, 2016, AIDS Research and Therapy.

Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program

I. Grant, T. Harrer, D. Podzamczer, 2013 .

The development and validation of a novel LC-MS/MS method for the quantification of Cenicriviroc in human plasma and cerebrospinal fluid.

A. Winston, S. Khoo, L. Else, 2019, Biomedical chromatography : BMC.

Special Issue: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2013 update)

C. Leen, A. Winston, C. Sabin, 2014 .

Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV

Hongbo Deng, A. Winston, C. Sabin, 2022, Kidney international reports.

Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIV

Hongbo Deng, A. Winston, C. Sabin, 2021, Kidney international reports.

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

P. Klenerman, A. Winston, G. Screaton, 2022, JCI insight.

Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.

B. Gazzard, I. Williams, A. Winston, 2012, JAMA.

Increased brain-predicted aging in treated HIV disease

David J. Sharp, Robert Leech, James H. Cole, 2017, Neurology.

Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir

D. Fuchs, A. Winston, A. Boasso, 2018, Journal of NeuroVirology.

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

M. Hernán, D. Podzamczer, A. Winston, 2014, Neurology.

The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype

A. Winston, G. Cooke, N. Mackie, 2013, AIDS.

A tale of two countries: all‐cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada

B. Gazzard, C. Leen, B. Yip, 2017, HIV medicine.

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.

D. Podzamczer, A. Winston, M. Das, 2018, The lancet. HIV.

Drug treatment for adults with HIV infection

A. Winston, B. Peters, Miriam Samuel, 2015, BMJ : British Medical Journal.

Factors influencing lopinavir and atazanavir plasma concentration.

B. Gazzard, C. Leen, D. Pillay, 2010, The Journal of antimicrobial chemotherapy.

Cerebrospinal fluid TPPA titres in the diagnosis of neurosyphilis

A. Winston, D. Goldmeier, Fareed Shiva, 2020, Sexually Transmitted Infections.

Pgp3 Antibody Enzyme-Linked Immunosorbent Assay, a Sensitive and Specific Assay for Seroepidemiological Analysis of Chlamydia trachomatis Infection

Anne M Johnson, A. Winston, R. Reynolds, 2009, Clinical and Vaccine Immunology.

Pgp3 Antibody Enzyme-Linked Immunosorbent Assay, a Sensitive and Specific Assay for Seroepidemiological Analysis of Chlamydia trachomatis Infection

Anne M Johnson, A. Winston, R. Reynolds, 2009 .

Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapy

A. Winston, D. Cooper, D. Marriott, 2006, HIV medicine.

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers

B. Gazzard, A. Winston, M. Boffito, 2006, AIDS.

Increasing detection of asymptomatic syphilis in HIV patients

B. Azadian, D. Hawkins, A. Winston, 2005, Sexually Transmitted Infections.

Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile?

A. Winston, D. Cooper, J. Amin, 2006, Sexually Transmitted Infections.

Is increased surveillance for asymptomatic syphilis in an HIV outpatient department worthwhile?

B. Azadian, D. Hawkins, A. Winston, 2003, Sexually transmitted infections.

Observational cohort study of rilpivirine (RPV) utilization in Europe

C. Leen, A. Mocroft, R. Paredes, 2022, AIDS Research and Therapy.

Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study

A. Winston, R. Price, B. Brew, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

P. Klenerman, A. Winston, G. Screaton, 2021 .

Respiratory symptoms and chronic bronchitis in people with and without HIV infection

A. Winston, C. Sabin, F. Post, 2020, HIV medicine.

Measuring and managing cognitive impairment in HIV.

A. Winston, S. Nightingale, 2017, AIDS.

HIV‐associated central nervous system diseases in the recent combination antiretroviral therapy era

B. Gazzard, C. Leen, D. Pillay, 2011, European journal of neurology.

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines

A. Winston, R. Shattock, J. Harker, 2022, PLoS Pathogens.

HIV cure strategies: response to ignore the central nervous system at your patients' peril.

A. Winston, S. Fidler, F. Julie, 2017, AIDS.

First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines: a cohort study.

A. Winston, C. Sabin, A. Phillips, 2020, AIDS.

Cerebrospinal fluid exposure of cenicriviroc in HIV‐positive individuals with cognitive impairment

A. Winston, S. Khoo, L. Else, 2019, British journal of clinical pharmacology.

Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individuals

A. Winston, C. Sabin, A. Milinkovic, 2019, International journal of STD & AIDS.

Cardiovascular disease in women living with HIV: A narrative review.

A. Winston, C. Sabin, S. Tariq, 2018, Maturitas.

Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia

C. Leen, M. Pirmohamed, L. Haddow, 2016, Journal of NeuroVirology.

Superior neurocognitive function is associated with central nervous system antiretroviral drug penetration only in regimens containing more than three antiretroviral agents.

A. Winston, C. Sabin, L. Garvey, 2011, AIDS.

Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study

A. Winston, A. Hill, G. Fätkenheuer, 2010, HIV clinical trials.

Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment.

A. Winston, A. Everitt, N. Mackie, 2009, AIDS.

Raltegravir: a new choice in HIV and new chances for research

A. Winston, S. Emery, 2009, The Lancet.

Skeletal muscle mitochondrial dysfunction in contemporary antiretroviral therapy: a single cell analysis

A. Winston, C. Sabin, A. Vincent, 2022, AIDS.

Psychiatric Symptoms in Patients Receiving Dolutegravir

A. Winston, M. Aboud, V. Vannappagari, 2017, Journal of acquired immune deficiency syndromes.

Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor

A. Winston, L. Garvey, 2009, Expert opinion on investigational drugs.

Current Challenges and Solutions for Clinical Management and Care of People with HIV: Findings from the 12th Annual International HIV and Aging Workshop.

J. Margolick, A. Winston, G. Kuchel, 2022, AIDS research and human retroviruses.

The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series

A. d’Arminio Monforte, A. Winston, A. Antinori, 2021 .

Neurological complications of HIV

A. Winston, A. Croucher, 2013 .

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus

P. Klenerman, A. Winston, E. Barnes, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication

C. Leen, D. Pillay, A. Winston, 2008, Antiviral therapy.

The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.

A. Winston, D. Cooper, M. Law, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.

J. Allsop, A. Winston, S. Taylor-Robinson, 2012, The Journal of antimicrobial chemotherapy.

Molecular neuroimaging of inflammation in HIV

A. Winston, J. Alagaratnam, 2021, Clinical and experimental immunology.

Responses to Quadrivalent Influenza Vaccine Reveal Distinct Circulating CD4+CXCR5+ T Cell Subsets in Men Living with HIV

Graham W. Taylor, A. Winston, G. Cooke, 2019, Scientific Reports.

Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.

A. Winston, S. Khoo, D. Back, 2013, The Journal of antimicrobial chemotherapy.

The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations

C. Leen, A. Winston, C. Sabin, 2013, HIV medicine.

Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021

O. Kirk, A. Winston, C. Marzolini, 2022, HIV medicine.

The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients

A. Winston, D. Back, L. Dickinson, 2010, Antiviral therapy.

Efficacy of protease inhibitor monotherapy vs. triple therapy: meta‐analysis of data from 2303 patients in 13 randomized trials

A. Winston, A. Hill, N. Paton, 2016, HIV medicine.

The global burden of cognitive impairment in people with HIV

A. Winston, C. Sabin, Lea D. Keng, 2022, AIDS (London, England).

Short Communication: Nonnucleoside Reverse Transcriptase Inhibitor Fold Change or Plasma Concentration as a Predictor of Virological Response over 48 Weeks in Highly Treatment Experienced HIV-Positive Individuals

A. Winston, D. Cooper, S. Emery, 2006 .

Biomarker associations with insomnia and secondary sleep outcomes in persons with and without HIV in the POPPY-Sleep substudy: a cohort study

S. Redline, A. Winston, C. Sabin, 2022, Sleep.

British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2015

C. Leen, A. Winston, C. Sabin, 2016, HIV medicine.

British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)

C. Leen, A. Winston, C. Sabin, 2014, HIV medicine.

7.0 Managing virological failure

C. Leen, A. Winston, C. Sabin, 2012, HIV medicine.

Pain in people living with HIV and its association with healthcare resource use, well being and functional status

A. Winston, C. Sabin, M. Johnson, 2018, AIDS.

Defining cognitive impairment in people-living-with-HIV: the POPPY study

A. Winston, C. Sabin, J. Underwood, 2016, BMC Infectious Diseases.

Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

A. Winston, R. Price, B. Brew, 2015, HIV medicine.

Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?.

A. Winston, K. Robertson, J. Underwood, 2015, AIDS.

Controversies in HIV-associated neurocognitive disorders

A. Winston, S. Khoo, J. McArthur, 2014, The Lancet Neurology.

Neurocognitive Function in HIV Infected Patients on Antiretroviral Therapy

C. Leen, A. Winston, C. Orkin, 2013, PloS one.

The first point prevalence study of genital Chlamydia trachomatis infection in young male inmates in the UK

A. Winston, G. Matthews, A. Menon-Johansson, 2005, International journal of STD & AIDS.

Chlamydia trachomatis Pgp3 Antibody Persists and Correlates with Self-Reported Infection and Behavioural Risks in a Blinded Cohort Study

A. Winston, N. Dickson, D. Kounali, 2016, PloS one.

CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies.

A. Winston, P. Reiss, M. Guiguet, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial

S. Trottier, A. Winston, B. Conway, 2018, The Journal of antimicrobial chemotherapy.

Transmission of monkeypox virus through sexual contact – A novel route of infection

A. Winston, D. Price, T. Rampling, 2022, The Journal of infection.

Defining cerebrospinal fluid HIV RNA escape: editorial review AIDS.

A. Winston, R. Price, S. Letendre, 2019, AIDS.

Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?

A. Winston, S. Khoo, 2008, Current opinion in HIV and AIDS.

Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy

A. Winston, S. Taylor-Robinson, D. Cooper, 2012, Neuroradiology.

An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs

D. Pillay, A. Winston, C. Sabin, 2017, The Journal of antimicrobial chemotherapy.

Rilpivirine:anovelnon-nucleoside reversetranscriptaseinhibitor

A. Winston, L. Garvey, 2009 .

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.

A. Winston, D. Cooper, D. Marriott, 2005, Journal of Antimicrobial Chemotherapy.

Host determinants of antiretroviral drug activity

A. Winston, A. Owen, M. Boffito, 2005, Current opinion in infectious diseases.

The clinical pharmacology of antiretrovirals in development

A. Winston, M. Boffito, P. Mallon, 2006, Expert opinion on drug metabolism & toxicology.

High Treatment Success Rates When Switching to Once Daily Nevirapine Containing Antiretroviral Therapy

A. Winston, N. Mackie, Brett Marett, 2008, The open AIDS journal.

Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure

C. Leen, D. Pillay, R. Gilson, 2014, The Journal of infectious diseases.

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV

B. Gazzard, C. Leen, C. Fraser, 2019, Journal of virus eradication.

Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase

B. Gazzard, D. Pillay, A. Winston, 2004, AIDS.

Combining resistance and pharmacology for optimum patient care

A. Winston, S. Khoo, D. Back, 2007, Current opinion in HIV and AIDS.

Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.

H. Jessen, A. Winston, D. Cooper, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

H. Jessen, A. Winston, D. Cooper, 2015, The Lancet. Infectious diseases.

Emerging concepts on the use of antiretroviral therapy in older adults living with HIV infection

A. Winston, J. Underwood, 2015, Current opinion in infectious diseases.

Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.

A. Waldman, A. Winston, S. Khoo, 2014, The Journal of antimicrobial chemotherapy.

Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial

A. Winston, M. Johnson, M. Gompels, 2015, The lancet. HIV.

Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials

A. Winston, A. Hill, N. Paton, 2014, Journal of the International AIDS Society.

Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine

A. Winston, H. Teppler, Valerie Teal, 2020, AIDS.

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine

A. Winston, L. Waters, N. Perry, 2011, AIDS.

Lack of response of anal intra-epithelial neoplasia to highly active antiretroviral therapy.

B. Gazzard, A. Winston, M. Bower, 2003, AIDS.

Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?

B. Gazzard, A. Winston, D. Back, 2004, AIDS.

Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial

A. Winston, Rebekah and Puls, group Encore CSF Sub‐study, 2014, Journal of the International AIDS Society.

Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.

A. Winston, S. Khoo, M. Boffito, 2016, The Journal of antimicrobial chemotherapy.

The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age

A. Winston, M. Boffito, D. Back, 2015, HIV clinical trials.

Differences in the Direction of Change of Cerebral Function Parameters Are Evident over Three Years in HIV-Infected Individuals Electively Commencing Initial cART

A. Winston, S. Taylor-Robinson, D. Cooper, 2015, PLoS ONE.

The use of D-dimers in the diagnosis of occult pulmonary emboli in HIV pulmonary disease — two case reports

A. Winston, B. Gazzard, M. Nelson, 2000, International journal of STD & AIDS.

Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART

D. Brooks, A. Winston, M. Politis, 2014, AIDS.

Neuroinflammation in treated HIV-positive individuals

Roger N Gunn, Qi Guo, Paul M Matthews, 2016, Neurology.

Cognitive Function in Young Persons With and Without Perinatal HIV in the AALPHI Cohort in England: Role of Non-HIV-Related Factors.

A. Winston, D. Gibb, A. Arenas-Pinto, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Can antiretroviral therapy prevent HIV-associated cognitive disorders?

A. Winston, J. Vera, 2014, Current opinion in HIV and AIDS.

HIV, dementia and antiretroviral drugs: 30 years of an epidemic

A. Winston, H. Jäger, H. Manji, 2013, Journal of Neurology, Neurosurgery & Psychiatry.

The clinical implications of antiretroviral pharmacogenomics.

A. Winston, J. Fox, M. Boffito, 2006, Pharmacogenomics.

No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach

A. Winston, M. Johnson, H. Zetterberg, 2021, Journal of virus eradication.

Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy

B. Berkhout, A. Winston, C. Sabin, 2021, eLife.

Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels as compared with therapy based on protease inhibitors

B. Berkhout, A. Winston, C. Sabin, 2021 .

Factors Associated With Nonadherence to Antiretroviral Therapy Among Young People Living With Perinatally Acquired HIV in England

A. Winston, D. Gibb, A. Arenas-Pinto, 2020, The Journal of the Association of Nurses in AIDS Care : JANAC.

Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis

J. Farrar, M. Pirmohamed, A. Winston, 2016, Antimicrobial Agents and Chemotherapy.

Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study

C. Leen, D. Pillay, R. Gilson, 2017, The lancet. HIV.

Cognitive function and drivers of cognitive impairment in a European and a Korean cohort of people living with HIV

A. Winston, C. Sabin, P. Reiss, 2019, International journal of STD & AIDS.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Mortality and AIDS‐defining events among young people following transition from paediatric to adult HIV care in the UK

A. Winston, C. Sabin, F. Post, 2021, HIV medicine.

Host pharmacogenetics in the treatment of HIV and cancer.

A. Winston, E. Hatzimichael, M. Bower, 2006, Current drug safety.

Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational cross‐sectional analysis

A. Winston, C. Sabin, D. De Francesco, 2020, HIV medicine.

Factors associated with obesity in the POPPY Cohort: an observational cross-sectional analysis

A. Winston, J. Anderson, I. Williams, 2020 .

Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study.

A. Winston, C. Sabin, M. Johnson, 2018, International journal of epidemiology.

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol

R. Cortese, A. Nicosia, V. Libri, 2017, Scientific Reports.

Do people living with HIV experience greater age advancement than their HIV-negative counterparts?

C. Franceschi, A. Winston, C. Sabin, 2018, AIDS.

Development and application of a new measure of engagement in out‐patient HIV care

B. Gazzard, C. Leen, D. Pillay, 2016, HIV Medicine.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

P. Klenerman, A. Winston, G. Screaton, 2021, The Lancet HIV.

Hiv-Associated Neurocognitive Disease: Case Studies and Suggestions for Diagnosis and Management in Different Patient Subgroups

A. Winston, A. Pozniak, H. Manji, 2014, Antiviral therapy.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment Among HIV-infected Individuals

D. Fuchs, A. Winston, R. Ellis, 2016, International journal of tryptophan research : IJTR.

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

O. Kirk, A. Wensing, A. Winston, 2020, HIV medicine.

The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.

B. Gazzard, D. Pillay, A. Winston, 2002, AIDS.

Objective and subjective rapid frailty screening tools in people with HIV

A. Winston, J. Walsh, O. Dosekun, 2020, HIV Medicine.

Effect of time since exposure to Chlamydia trachomatis on chlamydia antibody detection in women: a cross-sectional study

Anne M Johnson, A. Winston, R. Reynolds, 2013, Sexually Transmitted Infections.

Evaluating virological outcomes in people with HIV on stable antiretroviral therapy with reduced frequency of HIV viral load monitoring during the COVID‐19 pandemic

A. Winston, C. Sabin, S. Fidler, 2023, HIV medicine.

Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive Individuals

A. Winston, J. Underwood, 2016, Current HIV/AIDS Reports.

Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis

A. Winston, H. Zetterberg, J. Underwood, 2021, BMJ Neurology Open.

No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts

A. Winston, J. Lundgren, R. Price, 2018, AIDS (London).

Dynamics of cognitive change in HIV‐infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study

A. Winston, S. Taylor-Robinson, C. Duncombe, 2012, HIV medicine.

Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls

C. Franceschi, A. Winston, C. Sabin, 2017, PloS one.

Cognitive Health in Persons With Human Immunodeficiency Virus: The Impact of Early Treatment, Comorbidities, and Aging

A. Winston, S. Letendre, P. Cinque, 2023, The Journal of infectious diseases.

Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA

A. Winston, R. Swanstrom, R. Price, 2016, Journal of virus eradication.

Changes in functional connectivity in people with HIV switching antiretroviral therapy

M. Bozzali, M. Cercignani, A. Winston, 2020, Journal of NeuroVirology.

Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment

R. Leech, A. Winston, C. Sabin, 2018, PloS one.

Anxiety and depression symptoms in young people with perinatally acquired HIV and HIV affected young people in England

A. Winston, D. Gibb, A. Arenas-Pinto, 2018, AIDS care.

The use of a triple nucleoside‐nucleotide regimen for nonoccupational HIV post‐exposure prophylaxis

A. Winston, J. Amin, A. Carr, 2005, HIV medicine.

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

A. Borobia, H. Schuitemaker, Andrew Gibson, 2022, The Lancet Infectious Diseases.

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

S. McCormack, V. Libri, A. Winston, 2021, eClinicalMedicine.

EFFECTS OF ACTIVE HCV REPLICATION ON NEUROLOGIC STATUS IN HIV RNA VIRALLY SUPPRESSED PATIENTS

A. Winston, S. Taylor-Robinson, H. Pflugrad, 2010, Neurology.

Pharyngeal gonorrhoea – is dual therapy the way forward?

A. Winston, L. Sathia, B. Ellis, 2007, International journal of STD & AIDS.

The predictors of pain extent in people living with HIV.

A. Winston, C. Sabin, M. Johnson, 2020, AIDS.

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults

A. Winston, R. Koup, D. Douek, 2011, BMJ Open.

Sleep health and cognitive function among people with and without HIV: the use of different machine learning approaches

S. Redline, M. Rueschman, L. Haddow, 2021, Sleep.

Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.

A. Winston, T. Rawson, A. Everitt, 2012, The Journal of infection.

Clinical implications of antiretroviral pharmacokinetics and pharmacodynamics in the CNS

A. Winston, L. Garvey, 2009 .

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance

B. Gazzard, A. Winston, M. Boffito, 2007, AIDS.

Antiretroviral therapy CNS penetration and HIV-1–associated CNS disease

B. Gazzard, C. Leen, D. Pillay, 2011, Neurology.

Cerebrospinal fluid HIV RNA in persons living with HIV

A. Winston, A. Everitt, D. Muir, 2018, HIV medicine.

Cognitive disorders in people living with HIV.

A. Winston, S Spudich, 2020, The lancet. HIV.

No Evidence for Accelerated Aging-Related Brain Pathology in Treated Human Immunodeficiency Virus: Longitudinal Neuroimaging Results From the Comorbidity in Relation to AIDS (COBRA) Project

D. Sharp, R. Leech, A. Winston, 2018, Clinical Infectious Diseases.

Acute HCV/HIV Coinfection Is Associated with Cognitive Dysfunction and Cerebral Metabolite Disturbance, but Not Increased Microglial Cell Activation

J. Allsop, D. Brooks, A. Winston, 2012, PloS one.

High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid

C. Franceschi, B. Berkhout, R. Leech, 2017, Open forum infectious diseases.

Patterns of Co-occurring Comorbidities in People Living With HIV

A. Winston, C. Sabin, P. Reiss, 2018, Open forum infectious diseases.

Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV.

A. Winston, C. Sabin, M. Johnson, 2019, AIDS (London).

Level of agreement between frequently used cardiovascular risk calculators in people living with HIV

A. Winston, C. Sabin, M. Youle, 2019, HIV medicine.

Low Rates of Neurocognitive Impairment Are Observed in Neuro-Asymptomatic HIV-Infected Subjects on Effective Antiretroviral Therapy

A. Winston, V. Surendrakumar, L. Garvey, 2011, HIV clinical trials.

Sleep Disorders in Human Immunodeficiency Virus: A Substudy of the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) Study.

S. Redline, L. Haddow, A. Winston, 2020, Open forum infectious diseases.

Cerebral function tests reveal differences in HIV-infected subjects with and without chronic HCV co-infection.

P. Maruff, A. Winston, S. Taylor-Robinson, 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Atherosclerosis is Evident in Treated HIV-Infected Subjects With Low Cardiovascular Risk by Carotid Cardiovascular Magnetic Resonance

D. Pennell, W. Banya, A. Winston, 2016, Journal of acquired immune deficiency syndromes.

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

P. Klenerman, A. Winston, A. Goodman, 2021, SSRN Electronic Journal.

HIV-1 CNS in vitro infectivity models based on clinical CSF samples.

A. Winston, C. Herrera, R. Shattock, 2016, The Journal of antimicrobial chemotherapy.

High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving to adulthood.

A. Winston, S. Fidler, J. Ashby, 2010, Journal of acquired immune deficiency syndromes.

Associations between cognitive impairment and patient‐reported measures of physical/mental functioning in older people living with HIV

A. Winston, C. Sabin, J. Underwood, 2017, HIV medicine.

Changes in multimorbidity burden over a 3–5 year period among people with HIV

A. Winston, C. Sabin, D. De Francesco, 2023, Frontiers in Systems Biology.

Self-management Interventions for Pain and Physical Symptoms Among People Living With HIV: A Systematic Review of the Evidence

A. Winston, C. Sabin, R. Harding, 2018, Journal of acquired immune deficiency syndromes.

Evolution of changes in cognitive function after the initiation of antiretroviral therapy

A. Winston, J. Underwood, Stephen Taylor, 2016, AIDS research and therapy.

BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022

C. Leen, A. Winston, C. Sabin, 2022, HIV medicine.

Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals

A. Winston, S. Khoo, A. Clarke, 2018, AIDS.

Alterations in Cerebrospinal Fluid Chemokines Are Associated With Maraviroc Exposure and In Vivo Metabolites Measurable by Magnetic Resonance Spectroscopy

J. Allsop, A. Winston, S. Taylor-Robinson, 2012, HIV clinical trials.

CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF☆

C. Leen, M. Pirmohamed, L. Haddow, 2016, Cytokine.

Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls

J. Allsop, A. Winston, S. Taylor-Robinson, 2015, HIV clinical trials.

Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.

D. Podzamczer, B. Clotet, A. Winston, 2020, The Journal of antimicrobial chemotherapy.

Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation

B. Gazzard, D. Webster, C. Leen, 2015, HIV medicine.

Cognitive impairment in people living with HIV: consensus recommendations for a new approach

B. Ances, A. Winston, N. Nakasujja, 2023, Nature Reviews Neurology.

Cognitive Impairment in a Clinical Setting.

A. Waldman, A. Winston, J. Underwood, 2017, Journal of acquired immune deficiency syndromes.

Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir–Ritonavir Plus Either Raltegravir or Tenofovir–Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial

H. Amièva, A. d’Arminio Monforte, A. Winston, 2017, Journal of acquired immune deficiency syndromes.

Host and disease factors are associated with cognitive function in European HIV‐infected adults prior to initiation of antiretroviral therapy

H. Amièva, A. Winston, A. Antinori, 2016, HIV medicine.

Ask the Experts: Management of HIV-associated cognitive impairment

A. Winston, S. Rackstraw, 2013 .

Response to "Persistence of Neuropsychologic Deficits Despite Long-Term Highly Active Antiretroviral Therapy in Patients With HIV-Related Neurocognitive Impairment".

A. Winston, E. Thomson, J. Main, 2007, Journal of acquired immune deficiency syndromes.

Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study

A. Winston, C. Sabin, P. Reiss, 2021, Journal of Neurovirology.

Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance

C. Leen, C. Fraser, E. Volz, 2018, The Journal of antimicrobial chemotherapy.

Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues

A. Winston, A. Hill, C. Moecklinghoff, 2012, International journal of STD & AIDS.

Biomarkers of central and peripheral inflammation mediate the association between HIV and depressive symptoms

A. Winston, C. Sabin, P. Reiss, 2023, Translational psychiatry.

Plasma Biomarkers of HIV-associated Cognitive Disease

A. Winston, J. Underwood, 2015, EBioMedicine.

High‐risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV‐positive men who have sex with men

A. Winston, C. Sabin, F. Post, 2018, HIV Medicine.

Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.

X. Golay, L. Haddow, A. Winston, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial

D. Fuchs, A. Winston, S. Khoo, 2021, HIV research & clinical practice.

Correlation between computerised and standard cognitive testing in people with HIV and HIV-negative individuals

L. Haddow, A. Winston, C. Sabin, 2020, AIDS care.

Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV‐negative controls

A. Winston, C. Sabin, J. Underwood, 2019, HIV medicine.

Does acute hepatitis C infection affect the central nervous system in HIV‐1 infected individuals?

A. Winston, S. Taylor-Robinson, E. Thomson, 2009, Journal of viral hepatitis.

Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART

A. Winston, J. Fox, M. Nelson, 2019, Brain sciences.

Cerebrospinal fluid virology in people with HIV

A. Winston, A. Everitt, N. Mackie, 2023, HIV medicine.

Correlations between computerized battery testing and a memory questionnaire for identification of neurocognitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy.

A. Winston, D. Yerrakalva, L. Garvey, 2009, AIDS research and human retroviruses.

Learning and memory function in young people with and without perinatal HIV in England

A. Winston, D. Gibb, A. Arenas-Pinto, 2022, PloS one.

Neurocognitive Function in HIV-Infected Patients: Comparison of Two Methods to Define Impairment

A. Winston, J. Ainsworth, J. Day, 2014, PloS one.

P.0222 Brain connectivity and patient-reported outcomes in people with human immunodeficiency virus with symptoms of insomnia, switching integrase inhibitor-based antiretroviral therapy

M. Cercignani, A. Winston, C. Rae, 2021, European Neuropsychopharmacology.

Moving on from HAND: why we need new criteria for cognitive impairment in people with HIV and a proposed way forward.

A. Winston, M. Gisslén, D. Saylor, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals

A. Winston, D. Cooper, S. Emery, 2005, AIDS.

Raltegravir resistance in the cerebrospinal fluid

A. Winston, D. Cooper, B. Brew, 2013, Infection.

“I have failed to separate my HIV from this pain”: the challenge of managing chronic pain among people with HIV

A. Winston, C. Sabin, R. Harding, 2021, AIDS care.

CSF HIV-RNA load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study

A. Winston, B. Brew, A. Antinori, 2022 .

Effects of different antiretroviral agents on cerebral function in HIV-infected individuals

A. Winston, L. Garvey, 2011 .

Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice?

A. Winston, N. Mackie, S. Portsmouth, 2007, AIDS (London).

The management of HIV-1 protease inhibitor pharmacokinetic interactions.

A. Winston, M. Boffito, 2005, The Journal of antimicrobial chemotherapy.

COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

S. McCormack, V. Libri, A. Winston, 2023, eClinicalMedicine.

Polypharmacy and Drug–drug Interactions in Older and Younger People Living with HIV: The POPPY Study

A. Winston, C. Sabin, F. Post, 2019, Antiviral therapy.

An unusual abacavir reaction.

A. Winston, J. Fox, L. Greene, 2008, AIDS.

Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy

R. Paredes, A. Winston, J. Neaton, 2014, PloS one.

Predictive value of neurological symptoms in persons with suspected neurosyphilis

A. Winston, D. Goldmeier, Charlotte-Eve Short, 2021, Sexually Transmitted Infections.

Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.

A. Winston, I. Obiorah, O. Kon, 2008, AIDS research and human retroviruses.

Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir

D. Fuchs, A. Winston, A. Boasso, 2018, Journal of NeuroVirology.

Multivariate Pattern Analysis of Volumetric Neuroimaging Data and Its Relationship With Cognitive Function in Treated HIV Disease

D. Sharp, R. Leech, A. Winston, 2018, Journal of acquired immune deficiency syndromes.

Agreement between self-reported and objective measures of sleep in people with HIV and lifestyle-similar HIV-negative individuals

S. Redline, L. Haddow, A. Winston, 2021, AIDS.

Plasma NRTI concentration and their associations with liver and renal parameters in people living with HIV.

A. Winston, C. Sabin, S. Khoo, 2020, AIDS (London).

Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers.

A. Winston, L. Dickinson, J. Ashby, 2011, The Journal of antimicrobial chemotherapy.

Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct‐acting antivirals—Results from the EuroSIDA study

C. Leen, A. Mocroft, A. Winston, 2022, HIV medicine.

Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.

B. Gazzard, C. Leen, A. Winston, 2013, The Journal of antimicrobial chemotherapy.

Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions

M. Hernán, A. Winston, C. Sabin, 2017, Journal of acquired immune deficiency syndromes.

The K65R mutation in HIV-1 reverse transcriptase.

A. Winston, J. Stebbing, 2004, Journal of HIV therapy.

Validation of a Novel Multivariate Method of Defining HIV-Associated Cognitive Impairment

D. Sharp, A. Winston, C. Sabin, 2019, Open forum infectious diseases.

Chronic Kidney Disease Risk in African and Caribbean Populations With HIV

B. Gazzard, C. Leen, D. Pillay, 2018, The Journal of infectious diseases.

Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study

B. Gazzard, D. Webster, C. Leen, 2013, The Journal of antimicrobial chemotherapy.

Comorbidity indices in people with HIV and considerations for coronavirus disease 2019 outcomes

A. Winston, C. Sabin, D. De Francesco, 2020, AIDS.

Efficacy, safety and CNS effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine in a randomized controlled trial.

A. Winston, H. Teppler, Valerie Teal, 2021, AIDS.

Comorbidity Indices in People with HIV and Considerations for COVID-19 Outcomes

A. Winston, C. Sabin, F. Post, 2020 .

Association between inflammatory biomarker profiles and cardiovascular risk in individuals with and without HIV

L. Haddow, A. Winston, C. Sabin, 2022, AIDS.

Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

T. Harrer, A. Winston, E. Harrer, 2023, Scientific Reports.

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

M. Hernán, D. Podzamczer, A. Winston, 2014, Neurology.

HIV – the good news

A. Winston, C. Sabin, P. Mallon, 2018 .

Data linkage reduces loss to follow-up in an observational HIV cohort study.

B. Gazzard, C. Leen, A. Winston, 2010, Journal of clinical epidemiology.

Anticholinergic medications associated with falls and frailty in people with HIV

A. Winston, C. Sabin, F. Post, 2023, HIV medicine.

Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy.

C. Leen, A. Winston, C. Sabin, 2015, The Journal of allergy and clinical immunology.

Screening for syphilis in HIV-positive men who have sex with men (MSM)

D. Hawkins, A. Winston, D. Asboe, 2006, International Journal of STD and AIDS.

Response to: Asymptomatic neurocognitive impairment is a risk for symptomatic decline over a 3-year study period.

A. Winston, M. Gisslén, J. Joska, 2021, AIDS.

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV‐positive persons version 9.0

S. McCormack, A. Mocroft, O. Kirk, 2018, HIV medicine.

Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.

B. Gazzard, A. Winston, S. Khoo, 2006, Journal of acquired immune deficiency syndromes.

Cerebrospinal fluid HIV RNA escape symptomatology.

A. Winston, A. Antinori, P. Cinque, 2021, AIDS.

Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate

A. Winston, L. Campbell, B. Barbini, 2021, Journal of acquired immune deficiency syndromes.

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol

R. Cortese, A. Nicosia, V. Libri, 2017, Scientific Reports.

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

S. McCormack, V. Libri, A. Winston, 2022, eClinicalMedicine.

Factors influencing lopinavir and atazanavir plasma concentration.

B. Gazzard, C. Leen, D. Pillay, 2010, The Journal of antimicrobial chemotherapy.

Neuroinflammation in treated HIV-positive individuals

P. Matthews, A. Winston, E. Rabiner, 2016, Neurology.

Polypharmacy and Drug–drug Interactions in Older and Younger People Living with HIV: The POPPY Study

A. Winston, C. Sabin, F. Post, 2019, Antiviral therapy.

HIV, dementia and antiretroviral drugs: 30 years of an epidemic

A. Winston, H. Jäger, H. Manji, 2013, Journal of Neurology, Neurosurgery & Psychiatry.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

R. C. Rose, Todd M. Allen, David S. Rubin, 2010, Science.

Measuring and managing cognitive impairment in HIV.

A. Winston, S. Nightingale, 2017, AIDS.

Magnetic resonance imaging and spectroscopy of the brain in HIV disease.

A. Winston, H. Hyare, J. Stebbing, 2008, Journal of HIV therapy.

British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)

C. Leen, A. Winston, C. Sabin, 2014, HIV medicine.

Differences in the variability of cerebral proton magnetic resonance spectroscopy (1H-MRS) measurements within three HIV-infected cohorts

A. Winston, S. Taylor-Robinson, L. Garvey, 2015, The neuroradiology journal.

Measurement of Retinal Vessels as a Biomarker of Cerebrovascular Aging in Older HIV-Positive Men Compared With Controls

L. Haddow, R. Gilson, A. Winston, 2017, Journal of acquired immune deficiency syndromes.

CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF☆

C. Leen, M. Pirmohamed, L. Haddow, 2016, Cytokine.

Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation

Andrew L. Kerr, C. Leen, C. Fraser, 2020, HIV medicine.